.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB12_AlbinterferonAlfa2b.AlbinterferonAlfa2b .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB12_AlbinterferonAlfa2b.AlbinterferonAlfa2b| name: | AlbinterferonAlfa2b |
| ATC code: | L03AB12 | route: | subcutaneous |
| n-compartments | 2 |
Albinterferon alfa-2b is a recombinant fusion protein of human albumin and interferon alfa-2b developed as a long-acting form of interferon for the treatment of chronic hepatitis C infection. It was intended to offer less frequent dosing schedules compared to traditional pegylated interferons, but its development was discontinued and it is not approved or in clinical use.
Pharmacokinetic estimates for healthy adult subjects and patients with chronic hepatitis C, reported after subcutaneous administration.
Riggs, MM, et al., & Stein, DS (2012). Population pharmacokinetics and exposure-response of albinterferon alfa-2b. Journal of clinical pharmacology 52(4) 475–486. DOI:10.1177/0091270011399576 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21551316